Uncategorized
Nicox enters agreement with Eyevance for US commercialization of Zerviate
Nicox has signed an exclusive licensing agreement with Eyevance Pharmaceuticals for the commercialization of Zerviate in the United States, according to a Nicox press release.Eyevance will make a one-time upfront payment of $6 million to Nicox under the agreement, and Nicox is eligible to receive up to $42.5 million in future milestones.